Thermo Fisher Scientific (TMO) Expected to Announce Earnings on Wednesday

Thermo Fisher Scientific (NYSE:TMO) is expected to be announcing its Q2 2025 earnings results before the market opens on Wednesday, July 23rd. Analysts expect the company to announce earnings of $5.22 per share and revenue of $10.68 billion for the quarter. Thermo Fisher Scientific has set its FY 2025 guidance at 21.760-22.840 EPS.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the prior year, the firm earned $5.11 earnings per share. Thermo Fisher Scientific’s revenue was up .2% on a year-over-year basis. On average, analysts expect Thermo Fisher Scientific to post $23 EPS for the current fiscal year and $26 EPS for the next fiscal year.

Thermo Fisher Scientific Price Performance

TMO stock opened at $418.32 on Wednesday. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $627.88. The firm has a 50-day moving average of $409.67 and a 200 day moving average of $474.77. The company has a market cap of $157.91 billion, a P/E ratio of 24.53, a PEG ratio of 2.26 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.09%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on TMO shares. Royal Bank Of Canada decreased their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Wells Fargo & Company decreased their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, April 24th. Barclays cut their price target on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an “equal weight” rating on the stock in a report on Tuesday, June 24th. UBS Group cut shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating and cut their price target for the company from $500.00 to $460.00 in a report on Tuesday, July 8th. Finally, The Goldman Sachs Group set a $610.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Wednesday, April 23rd. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $600.30.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.33% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Thermo Fisher Scientific stock. Brighton Jones LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,409 shares of the medical research company’s stock after acquiring an additional 988 shares during the period. Brighton Jones LLC’s holdings in Thermo Fisher Scientific were worth $2,293,000 as of its most recent SEC filing. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.